



an Open Access Journal by MDPI

The Rise of Alternative (Non-) Antibody Scaffolds Therapeutics

Guest Editor:

Dr. João C. Fernandes

Centro de Biotecnologia e
Química Fina (CBQF), Escola
Superior de Biotecnologia,
Universidade Católica
Portuguesa, Amyris Bio Products
Portugal, 4169-005 Porto,
Portugal

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

The development of high-affinity antibodies has proved to be a valuable form of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Nevertheless, antibody-based therapeutics still face several challenges, limiting their widespread application, including high production costs, limited stability, suboptimal format for targeted payload delivery or poor tissue penetration. Limitations on whole antibodies application have led to the development and study of various antibody fragments and antibody-like scaffold proteins as alternatives for different therapeutic applications.

This Special Issue will focus on the development and application of antibody fragments (e.g., single-chain variable fragments, single domain antibody fragments) and nonantibody binding proteins (e.g., knottins, Kunitz domains, etc.) to the treatment of infections, autoimmune conditions, cancer, and neurological diseases.



mdpi.com/si/71635

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)